scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.DIABRES.2009.09.008 |
P698 | PubMed publication ID | 19796836 |
P50 | author | Mykola Khalangot | Q60660190 |
P2093 | author name string | Mykola Tronko | |
Victor Kravchenko | |||
Vladimir Kovtun | |||
P2860 | cites work | Primary care diabetes in Ukraine. | Q37218319 |
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | circulatory system | Q11068 |
P304 | page(s) | 247-253 | |
P577 | publication date | 2009-09-30 | |
P1433 | published in | Diabetes Research and Clinical Practice | Q15750054 |
P1476 | title | Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study | |
P478 | volume | 86 |
Q38374279 | Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review |
Q39565271 | Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population |
Q38364806 | Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. |
Q42738237 | Comment on: Pantalone et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010;33:1224-1229. |
Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
Q38754132 | Is gliclazide a sulfonylurea with difference? A review in 2016. |
Q44802551 | Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study |
Q38281461 | Mortality risk among sulfonylureas: a systematic review and network meta-analysis |
Q38248399 | Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations |
Q92432007 | PATIENTS TREATED WITH INSULIN AND SULPHONYLUREA ARE AT INCREASED MORTALITY RISK AS COMPARED WITH THOSE TREATED WITH INSULIN PLUS METFORMIN |
Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
Q46887711 | Response to Comment on: Pantalone et al. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A Retrospective Analysis. Diabetes Care 2010;33:1224–1229. |
Q43901204 | Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study |
Q27022613 | Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials |
Q50562456 | Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study. |
Q37878493 | Sulfonylureas: do we need to introspect safety again? |
Q37913528 | The future of incretin-based therapy: novel avenues--novel targets |
Q33873053 | The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis |
Q37961238 | Treating diabetes today with gliclazide MR: a matter of numbers |
Q37933466 | Variations in tissue selectivity amongst insulin secretagogues: a systematic review |
Search more.